JP5758289B2 - ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用 - Google Patents

ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用 Download PDF

Info

Publication number
JP5758289B2
JP5758289B2 JP2011509999A JP2011509999A JP5758289B2 JP 5758289 B2 JP5758289 B2 JP 5758289B2 JP 2011509999 A JP2011509999 A JP 2011509999A JP 2011509999 A JP2011509999 A JP 2011509999A JP 5758289 B2 JP5758289 B2 JP 5758289B2
Authority
JP
Japan
Prior art keywords
trkc
neurotrophin
receptor
fragment
trkc receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011509999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524516A5 (https=
JP2011524516A (ja
Inventor
パトリック、エチエンヌ、ロジェ、メラン
セルバン、マリー、セブリーヌ、トスジグ‐デラマスュル
セリーヌ、ジャクリーヌ、アンドレ、デロワ
ヒメナ、ボウサス‐ロドリゲス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecole Normale Superieure de Lyon
Original Assignee
Ecole Normale Superieure de Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Normale Superieure de Lyon filed Critical Ecole Normale Superieure de Lyon
Publication of JP2011524516A publication Critical patent/JP2011524516A/ja
Publication of JP2011524516A5 publication Critical patent/JP2011524516A5/ja
Application granted granted Critical
Publication of JP5758289B2 publication Critical patent/JP5758289B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
JP2011509999A 2008-05-21 2009-05-22 ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用 Expired - Fee Related JP5758289B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5505208P 2008-05-21 2008-05-21
US61/055.052 2008-05-21
PCT/EP2009/056253 WO2009141441A1 (en) 2008-05-21 2009-05-22 Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014253505A Division JP2015092170A (ja) 2008-05-21 2014-12-15 ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用

Publications (3)

Publication Number Publication Date
JP2011524516A JP2011524516A (ja) 2011-09-01
JP2011524516A5 JP2011524516A5 (https=) 2012-07-12
JP5758289B2 true JP5758289B2 (ja) 2015-08-05

Family

ID=40941707

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011509999A Expired - Fee Related JP5758289B2 (ja) 2008-05-21 2009-05-22 ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用
JP2014253505A Pending JP2015092170A (ja) 2008-05-21 2014-12-15 ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014253505A Pending JP2015092170A (ja) 2008-05-21 2014-12-15 ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用

Country Status (5)

Country Link
US (2) US20110229485A1 (https=)
EP (1) EP2294416A1 (https=)
JP (2) JP5758289B2 (https=)
CA (1) CA2724830A1 (https=)
WO (1) WO2009141441A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6929231B2 (ja) * 2015-05-29 2021-09-01 イグナイタ インコーポレイテッド Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348856A (en) * 1991-07-08 1994-09-20 E. R. Squibb & Sons, Inc. DNA encoding TRKC protein
US5789187A (en) * 1992-08-27 1998-08-04 Worcester Foundation For Experimental Biology Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
US20040058416A1 (en) * 1994-03-18 2004-03-25 Presta Leonard G. Human trk receptors and neurotrophic factor inhibitors
US6008003A (en) * 1997-10-28 1999-12-28 Promega Corporation Non-invasive diagnostic method for interstitial cystitis and bladder cancer
WO1999040103A1 (en) * 1998-02-10 1999-08-12 The Children's Medical Center Corporation Nt-3 and medulloblastoma
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
ATE446366T1 (de) * 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
JP2003231687A (ja) * 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
CN101218229A (zh) * 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
WO2007099133A1 (en) * 2006-02-28 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) Screening for anti-cancer compounds using netrin-1 activity
WO2008045627A2 (en) * 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof

Also Published As

Publication number Publication date
CA2724830A1 (en) 2009-11-26
JP2011524516A (ja) 2011-09-01
JP2015092170A (ja) 2015-05-14
US20140186364A1 (en) 2014-07-03
WO2009141441A1 (en) 2009-11-26
US20110229485A1 (en) 2011-09-22
EP2294416A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
US8309524B2 (en) Chimeric RGMa polypeptides
US9226963B2 (en) Antagonist anti-Rspondin3 antibodies
JP5602368B2 (ja) ネトリン−１活性を用いた抗癌化合物のスクリーニング
US20110212091A1 (en) Materials and methods for inhibiting cancer cell invasion
AU2006337085B2 (en) Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
CN107517590A (zh) 与表皮生长因子受体‑靶制剂有关的感受性预测用新型生物标志物及其用途
WO2009141440A1 (en) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma
JP5758289B2 (ja) ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用
CN105377296A (zh) 治疗肝癌的材料和方法
US7432051B2 (en) Erythropoietin and erythropoietin receptor expression in human cancer
Haase et al. Neurotensin receptors in adeno-and squamous cell carcinoma
KR20140144934A (ko) Ｃｔｈｒｃ１의 발현 및 활성 억제제를 유효성분으로 포함하는 췌장암 치료 및 전이억제용 조성물
US20210009673A1 (en) Methods for regulating breast cancers
KR101776864B1 (ko) Npffr2 억제제를 유효성분으로 포함하는 암 전이 억제 및 암 치료용 조성물
WO1999035283A1 (en) Methods and reagents for modulating cell motility
US9255272B2 (en) Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma
US20260053891A1 (en) Methods and compositions for treating cancer
JP2012529282A (ja) 治療薬および分析方法
JP7696343B2 (ja) がん治療における抗ＥｐＣＡＭ抗体の使用
KR101796091B1 (ko) 카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물
US8603764B2 (en) EphA kinase cancer diagnostic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150603

R150 Certificate of patent or registration of utility model

Ref document number: 5758289

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees